Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01721746 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 405
- Enrollment target
NCT01721746 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 405 participants.
The verdict
NCT01721746, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 405 participants
- Enrollment target
Study Summary
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Dacarbazine
- BIOLOGICAL BMS-936558
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2012-12-21 |
| Est. Completion | 2020-12-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01721746
The ClinicalTrials.gov registry entry for NCT01721746 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT01721746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01721746 about?
NCT01721746 is a clinical study titled "A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)". The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
What is the current status of trial NCT01721746?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 405 participants. The study started on 2012-12-21. Estimated completion is 2020-12-29.
What interventions are being tested in trial NCT01721746?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Dacarbazine (DRUG), BMS-936558 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01721746?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.